Ladrón Abia Pablo, Ortiz Vicente, García-Campos María, Saéz-González Esteban, Mínguez Sabater Alejandro, Izquierdo Rosa, Garrigues Vicente
Digestive Functional Disorders Unit, Gastroenterology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Digestive Functional Disorders Unit, Gastroenterology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Gastroenterol Hepatol. 2023 Apr;46(4):249-254. doi: 10.1016/j.gastrohep.2022.05.004. Epub 2022 May 20.
Retrospective studies have suggested that long-term use of opioids can cause esophageal motility dysfunction. A recent clinical entity known as opioid-induced esophageal dysfunction (OIED) has been postulated. There is no data from prospective studies assessing the incidence of opioid-induced effects on the esophagus.
Evaluate the incidence of OIED during chronic opioid therapy.
From February 2017 to August 2018, all patients seen in the Pain Unit of the hospital, who started opioid treatment for chronic non-neoplastic pain and who did not present esophageal symptoms previously, were included. The presence of esophageal symptoms was assessed using the Eckardt score after 3 months and 1 year since the start of the study. In February 2021, the clinical records of all included patients were reviewed to assess whether esophageal symptoms were present and whether opioid therapy was continued. In patients presenting with esophageal symptoms, an endoscopy was performed and, if normal, a high-resolution esophageal manometry was performed. For a confidence level of 95%, a 4% margin of error and an estimated prevalence of 4%, a sample size of 92 patients was calculated.
100 patients were included and followed while taking opioids, for a median of 31 months with a range between 4 and 48 months. Three women presented with dysphagia during the first 3 months of treatment, being diagnosed with esophagogastric junction outflow obstruction; type II and type III achalasia. The cumulative incidence of OIED was 3%; 95%-CI: 0-6%.
Chronic opioid therapy in patients with chronic non-neoplastic pain is associated with symptomatic esophageal dysfunction.
回顾性研究表明,长期使用阿片类药物可导致食管动力功能障碍。最近提出了一种称为阿片类药物引起的食管功能障碍(OIED)的临床实体。尚无前瞻性研究评估阿片类药物对食管影响的发生率的数据。
评估慢性阿片类药物治疗期间OIED的发生率。
纳入2017年2月至2018年8月期间在医院疼痛科就诊、开始接受阿片类药物治疗慢性非肿瘤性疼痛且既往无食管症状的所有患者。自研究开始3个月和1年后,使用埃卡德评分评估食管症状的存在情况。2021年2月,回顾所有纳入患者的临床记录,以评估是否存在食管症状以及是否继续进行阿片类药物治疗。对于出现食管症状的患者,进行内镜检查,若结果正常,则进行高分辨率食管测压。对于95%的置信水平、4%的误差幅度和4%的估计患病率,计算出样本量为92例患者。
100例患者在服用阿片类药物期间被纳入并随访,中位时间为31个月,范围在4至48个月之间。3名女性在治疗的前3个月出现吞咽困难,被诊断为食管胃交界部流出道梗阻;II型和III型贲门失弛缓症。OIED的累积发生率为3%;95%置信区间:0-6%。
慢性非肿瘤性疼痛患者的慢性阿片类药物治疗与有症状的食管功能障碍相关。